N-Alkylation by Hydrogen Borrowing: Pharmaceutical Applications and Comparison with Other Methods
Synthesis · 01.10.2025 · 57 (20) · 2893-2908
DOI: 10.1055/a-2646-8383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthesis, erschienen am 01.10.2025. Verfasst von Anju Nalikezhathu und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: National Science Foundation.
Abstract (Originalsprache)
Formation of C–N bonds is a quintessential transformation in organic synthesis. Among the various methods to access them, hydrogen borrowing catalysis offers a green, atom-economical, and cost-effective approach, with water being the sole by-product. In this reaction, amines are alkylated using alcohol coupling partners in the presence of a transition metal catalyst. Several catalytic systems have been developed and utilized in the synthesis of pharmaceutical intermediates and complex natural products, thereby replacing conventional amination reactions with hydrogen borrowing reactions that deliver improved selectivity and yield. In this short review, we compare hydrogen borrowing N-alkylation with other classical and modern C–N bond forming reactions and discuss applications in pharmaceutical synthesis.
Förderung
- National Science Foundation
Zitieren
APA
Nalikezhathu, A., & Williams, T. J. (2025). N-Alkylation by Hydrogen Borrowing: Pharmaceutical Applications and Comparison with Other Methods. Synthesis, 57(20), 2893-2908. https://doi.org/10.1055/a-2646-8383
Vancouver
Nalikezhathu A, Williams TJ. N-Alkylation by Hydrogen Borrowing: Pharmaceutical Applications and Comparison with Other Methods. Synthesis. 2025;57(20):2893-2908. doi:10.1055/a-2646-8383
BibTeX
@article{Nalikezhathu2025,
author = {Nalikezhathu, Anju and Williams, Travis J.},
title = {N-Alkylation by Hydrogen Borrowing: Pharmaceutical Applications and Comparison with Other Methods},
journal = {Synthesis},
year = {2025},
volume = {57},
number = {20},
pages = {2893--2908},
doi = {10.1055/a-2646-8383}
}
EUVIMED